BioCentury
ARTICLE | Clinical News

Lantus insulin glargine: Phase III started

November 19, 2012 8:00 AM UTC

Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Lantus insulin glargine Business: Endocrine/Metabolic Molecular target: Insulin receptor (INSR) Description: Synthetic sustained-release subcu...